Lantheus Holdings, Inc. $LNTH Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 94.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 71,943 shares of the medical equipment provider’s stock after selling 1,208,111 shares during the period. Assenagon Asset Management S.A.’s holdings in Lantheus were worth $4,788,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. First National Advisers LLC lifted its stake in Lantheus by 0.8% in the second quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock worth $2,292,000 after acquiring an additional 213 shares during the period. United Community Bank boosted its holdings in Lantheus by 15.6% in the third quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 245 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Lantheus during the 2nd quarter valued at $26,000. Concurrent Investment Advisors LLC raised its holdings in Lantheus by 10.3% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,936 shares of the medical equipment provider’s stock worth $202,000 after purchasing an additional 366 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its position in shares of Lantheus by 3.9% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock worth $819,000 after purchasing an additional 377 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Down 2.5%

NASDAQ:LNTH opened at $74.47 on Friday. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $108.91. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. The company’s 50-day simple moving average is $72.49 and its 200 day simple moving average is $63.33. The firm has a market capitalization of $4.85 billion, a P/E ratio of 22.10 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same quarter last year, the firm earned $1.59 earnings per share. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LNTH shares. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Wall Street Zen raised Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday. William Blair restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Finally, JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, February 27th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $86.14.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.